Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

6
HK stocks hit six-month closing low as trade war fears persist

2018-06-21 theedgemarkets
SHANGHAI (June 21): Hong Kong stocks ended at a six-month low on Thursday, as China-US trade conflict fears curbed risk appetite.
CRWOY 0390 CGHLY CRWOF 0914 CGHOF CEO 0384

0
China seen flexing loan muscle as it pushes farther into Pacific, tentacles reach Papua New Guinea

2018-06-18 japantimes.co.jp
CANBERRA – In the gritty, steamy streets of Papua New Guinea’s capital Port Moresby, signs of China’s push into the Pacific island nation are inescapable.
CRWOY 0390 CRWOF

0
China’s bid for global influence reaches the pacific islands

2018-06-18 malaymail
CANBERRA, June 18 — In the gritty, steamy streets of Papua New Guinea’s capital Port Moresby, signs of China’s push into the Pacific island nation are inescapable.
CRWOY 0390 CRWOF

0
High-speed rail builder China Railway swaps out debt for US$1.8 billion in fresh cash

2018-06-14 scmp
The company, at the forefront of the country’s ‘railway diplomacy’, is expected to play a big role in the country’s belt and road global trade push
CRWOY 1359 0390 CRWOF

0
HK stocks fall ahead of next week's Trump-Kim summit, Fed meeting

2018-06-08 theedgemarkets
SHANGHAI (June 8): Hong Kong stocks fell the most in two weeks on Friday, as investors braced for a series of market-moving events next week including the US-North Korea summit and the Federal Reserve's policy meeting.
SWRAY CRWOY SWRBY 0390 CGHLY CRWOF SWRBF SWRAF CGHOF 0384 1099

0
MSCI drops ZTE, four other companies from MSCI China A Inclusion Index

2018-05-30 reuters
SINGAPORE (Reuters) - Telecom equipment and smartphone maker ZTE Corp (000063.SZ) (0763.HK) and four other companies have been dropped from several MSCI indexes including the MSCI China A Inclusion Index as trading in the China-listed A shares of all five companies has been suspended.
CRWOY 0390 CRWOF

1
China’s Communists Rewrite the Rules for Foreign Businesses - The New York Times

2018-04-14 nytimes
The party is strengthening its influence — often gaining direct decision-making power — over the international firms doing business in China.
CRWOY 0489 0390 CRWOF 2601 NYTAB

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...